Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Zhenqiliujun cancer suppressant granules
- Development stage
- Preclinical
- Lead developer
- Southwest Medical University
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Zhenqiliujun cancer suppressant granules is a Traditional Chinese Medicine (TCM) formulation developed by the Department of Oncology at the Affiliated Hospital of Traditional Chinese Medicine, Southwest Medical University. It is primarily investigated as an adjuvant therapy for patients with metastatic colorectal cancer (mCRC). The granules are intended to be administered alongside standard first-line systemic treatments, such as mFOLFOX6 or FOLFIRI chemotherapy combined with targeted agents like bevacizumab or cetuximab. The formulation likely aims to enhance the efficacy of conventional therapies, mitigate side effects, and potentially modulate the immune microenvironment, though its specific molecular mechanisms remain a subject of clinical investigation.
- Other names
- Zhenqiliujun granules参芪六君抑癌颗粒
Beyond the preview
Go deeper on Zhenqiliujun cancer suppressant granules.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Zhenqiliujun cancer suppressant granules.